Product Description
Phenelzine is a potent, non-selective monoamine oxidase inhibitor (MAOI) used in treating depression and as an anxiolytic in adults. It is a hydrazine derivative drug and is one of the few remaining non-selective monoamine oxidase inhibitors (along with tranylcypromine and isocarboxazid) still in regular clinical use. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK554508/)
Mechanisms of Action: MAO Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Australia | Belgium | Canada | India | Ireland | Italy | New Zealand | Taiwan | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
07/10/2024 |
News Article |
Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics |
|
04/15/2024 |
News Article |
Acorda Therapeutics Announces Delisting from Nasdaq |
|
04/03/2024 |
News Article |
Acorda Therapeutics Announces Nasdaq Delisting Notification |
|
04/01/2024 |
News Article |
Acorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024 |